Effects of Isorhamnetin in Human Amniotic Epithelial Stem Cells in vitro and Its Cardioprotective Effects in vivo

Kazuhiro Aonuma1,2, Farhana Ferdousi2,3, DongZhu Xu2,4, Kenichi Tominaga2 and Hiroko Isoda1,2,3,5*

1 School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, Japan, 2 AIST-University of Tsukuba Open Innovation Laboratory for Food and Medicinal Resource Engineering (FoodMed-OIL), AIST, University of Tsukuba, Tsukuba, Japan, 3 Alliance for Research on the Mediterranean and North Africa (ARENA), University of Tsukuba, Tsukuba, Japan, 4 Cardiovascular Division, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 5 Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan

Cardiac hypertrophy and fibrosis are major pathophysiologic disorders that lead to serious cardiovascular diseases (CVDs), such as heart failure and arrhythmia. It is well known that transforming growth factor β (TGFβ) signaling pathways play a major role in the proliferation of cardiac hypertrophy and fibrosis, which is mainly stimulated by angiotensin II (AgII). This study aimed to investigate the cardioprotective potential of isorhamnetin (ISO) in human amniotic epithelial stem cells (hAESCs) through global gene expression analysis and to confirm its beneficial effects on cardiac hypertrophy and fibrosis in the AgII-induced in vivo model. In vitro, biological processes including TGFβ, collagen-related functions, and inflammatory processes were significantly suppressed in ISO pretreated hAESCs. In vivo, continuous AgII infusion using an osmotic pump induced significant pathological fibrosis and myocardial hypertrophy, which were remarkably suppressed by ISO pretreatment. ISO was found to reverse the enhanced TGFβ and Collagen type I alpha 1 mRNA expression induced by AgII exposure, which causes cardiovascular remodeling in ventricular tissue. These findings indicate that ISO could be a potential agent against cardiac hypertrophy and fibrosis.

Keywords: human amniotic epithelial stem cells, drug screening, isorhamnetin, cardiac fibrosis, angiotensin II, translational medicine

INTRODUCTION

Pathological cardiac fibrosis is a fundamental process in the excessive accumulation of extracellular matrix (ECM) such as collagen (Travers et al., 2016), which plays a key role in the disruption of the myocardial architecture, myocardial disarray, and electrical and mechanical cardiomyocyte dysfunction (Izawa et al., 2005). In addition, the loss of normal ECM structure impairs the integrity of cell-to-cell contraction, further isolates myocardial fibers, impairs oxygen supply, and causes atrophy and necrosis (Kai et al., 2006). Thus, cardiac fibrosis leads to various heart diseases, including cardiac hypertrophy, arrhythmia, and heart failure (Weber et al., 2008; Yue et al., 2011) and is considered an independent risk factor for cardiac morbidity and mortality (Bang et al., 2017;
Jin et al., 2018). Controlling hypertrophic remodeling and fibrotic changes may therefore offer a promising therapeutic strategy for reducing the cardiovascular disease (CVD) burden.

In recent years, increasing numbers of small molecules derived from or based on bioactive compounds of medicinal plants have been synthesized and screened for their potential therapeutic and preventative effects in CVD. However, the discovery of drugs is greatly hampered by the gap between the validation of the compound and its successful clinical application (Pott et al., 2020). One of the primary reasons for this translational inefficiency is the unpredictability of the currently used in vitro cellular models and the complexity of the in vivo microenvironment. Even the most high-throughput screening assays utilize monolayer cell cultures, where the crucial elements of drug-biology interactions are lost (Li and Kilian, 2015). Therefore, physiologically more relevant in vitro human models for screening and validation of thousands of compounds are in high demand in both academic research and the pharmaceutical industry. In this context, stem-cell-based approaches using human pluripotent stem cells, including both human embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC), have received great attention as effective tools for drug screening, not only for CVDs but also for other metabolic and neuronal diseases (Grskovic et al., 2011; Engle and Puppala, 2013). However, cell resources, ethical constraints, invasive extraction procedures, and expensive cell reprogramming and maintenance procedures make this type of stem cell less favorable as a practical source for drug screening (Chen et al., 2014).

In this context, human amniotic epithelial stem cells (hAESCs) possess substantial advantages over other stem cells. hAESCs are derived from term placenta after delivery and are discarded after birth. Therefore, they are readily available, do not require invasive harvesting procedures, and pose no ethical concerns. Most importantly, as hAESCs are derived from pluripotent epiblasts, they maintain ESC-like multilineage differentiation potential. Studies have shown that upon appropriate differentiation protocol, hAESCs can be differentiated into liver, pancreas and lung epithelium from endodermal origin, bone, and fat cells from mesodermal origin as well as neural cells from ectodermal origin (Miki et al., 2005, 2010; Toda et al., 2007; Parolini et al., 2008; Murphy et al., 2010; Zhou et al., 2013). Importantly, hAESCs also have cardiogenic and angiogenic differentiation potential (Miki et al., 2005; Fang et al., 2012; Wu et al., 2017; Serra et al., 2018). Furthermore, hAESCs have no tumorigenic, weak immunogenic, and strong immunomodulatory properties, and demonstrate mesenchymal stem cell (MSC)-like phenotypes as well (Miki, 2018; Yang et al., 2018; De Coppi and Atala, 2019). Thus, hAESCs provide an excellent model system for drug discovery.

At the University of Tsukuba Hospital, the Tsukuba Human Tissue Biobank Center (THB) was established in November 2013 with the aim to reserve human biospecimens to facilitate medical research (Takeuchi et al., 2016). Among a variety of cellular samples, hAESCs isolated from the donated full-term placenta are also preserved for research applications. In our previous studies, the stemness characteristics of hAESCs received from THB have been investigated (Ferdousi et al., 2019; Furuya et al., 2019). Although the primary amniotic epithelial cells were heterogenous, the hAESCs isolated from the adherent subpopulations of passed primary cells have widely expressed stemness markers. Besides, hAESCs cultured in a 3D microenvironment as spheroids, have highly expressed the stemness-related genes compared to their 2D counterpart as well as compared to iPSCs and MSCs (Ferdousi et al., 2019). We have previously investigated the gene expression profiles of several natural compounds in hAESCs (Ferdousi et al., 2019, 2020) in an effort to screen eligible natural compounds for further in-depth investigations. Among the compounds that we have screened in hAESCs,isorhamnetin (ISO) exerts cardiac morphogenesis, and antifibrotic potential.

Isorhamnetin, also known as 3-Methylquercetin or 3'- Methoxyquercetin, is one of the most common and widely distributed plant flavonols. It has anti-inflammatory, antioxidant, antiadipogenic, and antitumor activities (Hu et al., 2015; Yang et al., 2016). We have previously reported the anti-oxidant, antiobesity, and antifibrotic effects of ISO in rodent models (Zar Kalai et al., 2013; Ganbold et al., 2019). Ganbold et al. (2019) reported that ISO could alleviate steatosis and fibrosis in a non-alcoholic steatohepatitis (NASH) mouse model by reducing the expression of liver injury marker transforming growth factor β (Tgfβ), and the fibrogenic marker Collagen type I alpha 1 (Colla1). However, little is known about the possible protective effect of ISO against cardiac fibrosis or hypertrophy (Gao et al., 2017).

This study aimed to investigate the cardioprotective potential of ISO in hAESCs through global gene expression analysis and to observe its effect on angiotensin II (AgII)-induced fibrosis and hypertrophy in the myocardium of mice.

**MATERIALS AND METHODS**

**In vitro Study**

**hAESCs Extraction and Culture**

The procedure of cell isolation and cell culture have been explained elsewhere in detail (Ferdousi et al., 2019, 2020; Furuya et al., 2019). Briefly, hAESCs were obtained from the term placenta donated by mothers who underwent cesarean delivery. The amnion was washed with 200 mL of Hank’s Basic Salt Solution–Calcium and Magnesium Free (CMF-HBSS) after manual separation from the chorion and was cut into smaller pieces using a surgical scissor. The cells were maintained in placental epithelial cell basal medium (Promocell. # C-26140). The procedure of cell isolation and cell culture have been explained elsewhere in detail (Ferdousi et al., 2019, 2020; Furuya et al., 2019). Briefly, hAESCs were obtained from the term placenta donated by mothers who underwent cesarean delivery. The amnion was washed with 200 mL of Hank’s Basic Salt Solution–Calcium and Magnesium Free (CMF-HBSS) after manual separation from the chorion and was cut into smaller pieces using a surgical scissor. The cells were maintained in placental epithelial cell basal medium (Promocell. # C-26140). The medium was changed every 2–4 days. To subculture hAESCs, the plates were first washed twice with 10 mL of PBs. Then, 3 mL of pre-digestion buffer, pre-warmed to 37°C, was added to the plate. The cells were then incubated at 37°C for 5 min. Subsequently, 5 mL of 0.05% (w/v) trypsin-EDTA, pre-warmed to 37°C, was added to the plate and incubated at 37°C for 10 min. Finally, 5 mL of Dulbecco’s modified Eagle’s medium (DMEM) was added to stop the reaction. The cell suspension was then centrifuged twice at 200 rpm for 4 min at 4°C.
Lipidure was a co-supplement in the medium for hAESCs for screening of cardioprotective effects of isorhamnetin.

In vivo Study

Animal Preparation

Animal preparation: Male C57Bl/6 mice were (8 weeks of age; Japan Charles River Kanagawa, Japan) randomly assigned into three groups: control, AgII-administered group (AgII), and AgII and ISO-treated group (AgII + ISO). Mice in the AgII and AgII + ISO groups were continuously administered AgII (1,000 ng/kg/hr) with a mini-osmotic pump model (Alzet, model 2002, Cupertino, United States) for 2 weeks. Mice in the control group were infused with 0.85% saline. One week before the implantation of the mini-osmotic pumps, mice in the AgII + ISO group were administered ISO (5 mg/kg) intraperitoneally every day for 3 weeks. ISO was suspended in 0.1% dimethyl sulfoxide and 1% polypropylene glycol. Suspensions were freshly prepared and administered at a constant volume of 0.3 mL. Mice in the control and AgII groups were given the same volume of the vehicle solution (0.1% dimethyl sulfoxide, 1% polypropylene glycol, and normal saline) by intraperitoneal injection. Hearts were isolated immediately after exsanguination. Part of the left ventricles was fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis. The remaining left ventricles were kept in liquid nitrogen for further analysis.

Echocardiography

Echocardiography was performed using a Doppler echocardiographic system (Vevo 2100; Visual Sonics, Toronto, Canada). The mice were anesthetized with 1% isoflurane. Then, parasternal short-axis and parasternal long-axis 2D-guided echocardiographic views of the left ventricle (LV) were obtained at the level of the papillary muscles. The M-mode measurements of LV posterior wall thickness (LVPWT) and interventricular septal thickness (IVST) were obtained at the end of diastole and systole. LV mass was calculated using the following formula (Marwick et al., 2015):

\[
LV \text{ mass} = 1.04 \times [LVEDd + LVPWT + IVST]^3 - LVEDd^3) \times 0.8 + 0.6
\]

LVEDd = LV end-diastolic dimension

Histological Examination

Left ventricle was fixed in 4% paraformaldehyde and embedded in paraffin. The epicardium of the mid-lateral wall was cut into 2 μm thick sections. All specimens were stained with Masson trichrome (MT) and hematoxylin-eosin (H-E) stain and examined under a light microscope (BZX710; Keyence, Osaka, Japan). Transmural distribution of the percentage area of fibrosis was calculated as the total area of fibrosis (defined as the amount of collagen deposition stained with the aniline blue) divided by the sum of the total tissue area. Myocyte area was measured in ~50 cells at the site of a visible nucleus in each slide stained with H-E. The cross-sectional area of each myocyte (an average of 50 cardiomyocytes for each animal) was measured across the region corresponding to the visible nucleus in H-E stained slides.

Real-Time Polymerase Chain Reaction (RT-PCR)

Total RNA was extracted from ventricular tissue using an RNeasy Mini Kit (Qiagen, Valencia, CA, United States) according to the
suppliers protocol. Total RNA (1 µg) was reverse transcribed to cDNA using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Inc., Waltham, MA, United States). Real-time quantitative PCR was performed with PrimeTime Gene Expression Master Mix (Integrated DNA Technologies) on the ABI Prism 7500 FAST sequence detection system (Applied Biosystems, Foster City, CA, United States). The following primers were used for the experiment: natriuretic peptide B (Nppb; Mm.PT.588584045.g), Col1a1 (Mm.PT.587562513), Tgfβ1 (Mm.PT.5811254750), and Tgfβ2 (Mm.PT.5814105470). Gene expression levels were normalized to the housekeeping gene, 18S rRNA (4319413E, Thermo Fisher Scientific).

Chemicals
ISO was synthesized from quercetin (Fujifilm Wako Pure Chemical Corp., Tokyo, Japan) following the protocol of the National Institute of Advanced Industrial Science and Technology (Kato et al., 2016) and was used for in vitro and in vivo experiments. AgII was purchased from Wako Pure Chemical Industries Ltd (Osaka, Japan).

Statistical Analysis
Results are expressed as the mean ± standard deviation. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed to examine the differences between pairs of treatment groups. Differences were considered statistically significant at p < 0.05. All analyses were performed using IBM SPSS version 21.0 software (IBM Co., Armonk, NY, United States).

Ethical Considerations
The protocol for the hAESC study was reviewed and approved by the Ethical Review Committee of the University of Tsukuba. Informed written consent was obtained from the mothers who donated the placenta after delivery.

After receiving approval from the Institutional Animal Experiment Committee of the University of Tsukuba, animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, the Regulation for Animal Experiments in the University of Tsukuba, and the Fundamental Guideline for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology of Japan.

RESULTS
ISO Regulated Cardiac Development and Fibrosis-Associated GO and KEGG Pathways
A total of 1210 unique genes (after excluding duplicate probe IDs) were differentially expressed (fold change > 1.5; p < 0.05) in ISO-treated hAESCs compared to untreated controls at D10. Among them, 528 genes were significantly upregulated, whereas 682 genes were downregulated (Figure 1A). Compared to D0 control, a total of 3449 and 3884 genes were significantly (fold change > 2; p < 0.05) regulated in D10 control and D10 ISO-treated hAESCs, respectively (Supplementary Figure 1). Compared to undifferentiated hAESCs at D0, control hAESCs at D10 regulated epithelial-mesenchymal transition (EMT), cell cycle, cell division, autophagy, and apoptosis-associated GO (Supplementary Figure 1), whereas ISO-treated hAESCs regulated anti-inflammatory and TGFβ-related biological functions as well as EMT. The differentiation potential was toward myogenesis (Supplementary Figure 1). We have previously reported that the undifferentiated hAESC s expressed several stem cell markers, and the 3D hAESC spheroids showed significantly higher expression of stemness-related genes than their 2D counterparts.

In this article, we will mainly explain the GO enriched by DEGs between D10 ISO-treated and untreated control hAESCs. Significantly enriched biological processes included ECM organization, TGFβ and collagen-related processes, and anti-inflammatory functions. Both canonical and non-canonical Wnt signaling pathways and MAPK pathways were regulated. Cell adhesion, cell migration, wound healing, EMT, and apoptosis were also significantly regulated. Additionally, several cardiovascular development-associated pathways were also significantly regulated, which included but were not limited to heart development, angiogenesis, smooth muscle cell proliferation and migration, endothelial cell proliferation, artery morphogenesis, and blood vessel remodeling. Furthermore, ventricular cardiac muscle cell action potential, heart contraction, and myoblast differentiation-associated biological processes were significantly enriched (Figure 1B). Similarly, significantly enriched molecular functions included ECM structural constituents, elasticity, and binding as well as collagen binding, TGFβ binding, and fibronectin binding (Figure 1C). The most significant KEGG pathways were ECM-receptor interaction, focal adhesion, and PI3K-Akt, p53, TGFβ, MAPK, AMPK, and Jak-STAT pathways (Figure 1D). Heat map (Figure 1E) and boxplots (Figure 1F) show that fibrosis-associated genes had decreased expression profiles in ISO-treated hAESCs compared to untreated control cells. Finally, hierarchical cluster analysis of KEGG pathways and biological processes identified 33 clusters. The most significant cluster involved three KEGG pathways: ECM-receptor interaction, PI3K-Akt signaling pathway, and focal adhesion (enrichment score 4.89, Figure 1G). Genes involved in this cluster and their fold changes are listed in Supplementary Table 1.

ISO Abrogated AgII-Induced Ventricular Hypertrophy in vivo
To investigate the protective effect of ISO on abnormal cardiac structure induced by AgII, two-dimensional echocardiography was performed (Figures 2A,B). The echocardiography results indicate that the interventricular septum (IVS) and left ventricular posterior wall (LVPW) thickness, at both systole and diastole, were significantly increased in AgII-induced mice (p < 0.01 vs. control), while the increased IVS and LVPW thickness were significantly decreased by ISO treatment.
FIGURE 1 | (A) Scatter plot showing the distribution of DEGs by fold changes. The X-axis corresponds to the average signal intensity (log2) of each probe ID in D10 control hAESCs, and the Y-axis corresponds to the average signal intensity (log2) of each probe ID in D10 isorhamnetin-treated hAESCs. Blue dots represent the significantly downregulated and yellow dots represent the significantly upregulated DEGs (DEGs, differentially expressed genes with fold change >1.5; \( p < 0.05 \), one-way between-subjects ANOVA). The inset column graph shows the number of upregulated and downregulated DEGs (unique gene). Bar graphs showing the significantly enriched (\( p < 0.05 \); modified Fisher’s exact test) (B) biological processes, (C) molecular functions, and (D) KEGG pathways by the DEGs between D10 isorhamnetin-treated and D10 control hAESCs. The X-axis corresponds to the –log10 \( p \)-value. The number of DEGs is presented at the outer end of each bar. (E) Heatmap showing the expression intensity of selected cardiac fibrosis-associated genes. Heatmap was generated using an online tool Heatmapper (http://www.heatmapper.ca/). (F) Boxplots showing the comparison of expression intensity of all probe IDs of selected genes between D10 control and D10 isorhamnetin-treated hAESCs. Box ranges from 25th to 75th percentile, the line in the middle represents the median value, and the error bar represents the standard deviation (SD). Significance was computed by \( t \)-test for linear distributions and Mann-Whitney \( U \) test for non-linear distributions. (G) Table showing the most significantly enriched annotation cluster computed for KEGG pathways and biological processes. The enrichment score for this fibrosis-associated cluster was 4.89 (measurement criteria: Similarity threshold = 0.5, multiple linkage threshold = 0.5, and enrichment thresholds = 1.0).
FIGURE 2 | (A,B) Representative B-mode and M-mode echocardiograms of 11-week-old mice from the three groups. (C–G) Echocardiographic parameters, including IVS-s, IVS-d, LVPW-s, LVPW-d, and LV mass. Data were evaluated at 11 weeks in the Cont, AgII, and AgII + ISO groups (n = 5–7 per group). **P < 0.01 vs. Cont. ##P < 0.01 vs. AgII + ISO. IVST-s, LV interventricular septal thickness in systole; IVS-d, LV interventricular septal thickness in diastole; LVPWT-s, LV posterior wall thickness in systole; LVPWT-d, LV posterior wall thickness in diastole; LV, left ventricle.

(Figures 2C–F). In addition, B-mode images indicated that the walls of LV were enlarged by AgII and were restored by ISO treatment. Moreover, LV mass was significantly increased in the AgII-induced group. ISO could abrogate the AgII-induced increase in LV mass (Figure 2G).

ISO Reversed AgII-Induced Morphological Abnormalities in Cardiac Tissue in vivo

MT staining images showed that ISO significantly prevented the myocardial fibrotic responses induced by AgII (Figure 3A). Compared to the control group, H-E images showed severe disorganization of myofibrillar arrays, and cytoplasmic vacuolization and infiltration with neutrophil granulocytes in AgII-treated mice. ISO pretreatment remarkably reduced the pathological abnormalities (Figure 3B). The percentage of total fibrotic area was significantly increased in AgII-induced group, whereas ISO treatment could significantly reduce the percentage of fibroced area (Figure 3C). Furthermore, ISO significantly reduced the AgII-mediated increase in cardiomyocyte size (measured as cross-sectional area; CSA) (Figure 3D). The ratio of heart weight/body weight (HW/BW) was significantly increased by stimulation with AgII (p < 0.01 vs. control), while ISO significantly reduced the increase in HW/BW (Figure 3E).

ISO Prevented AgII-Induced Expression of Inflammatory and Fibrogenic Markers in Mouse Cardiac Tissue in vivo

To confirm the preventive effects of ISO on fibrogenic and hypertrophy markers observed in microarray analysis of hAESCs, we conducted RT-PCR in ventricular tissue to quantify the expression of Tgfβ1, Tgfβ2, Col1a1, and Nppb.

Tgfβ1 plays an important role in the development of myocardial fibrosis by promoting the production and deposition of collagens (Lijnen et al., 2000). AgII administration has been reported to increase the expression of Tgfβ1 in vivo, leading to cardiac fibrosis. In addition, overexpression of Tgfβ1 induces the mRNA expression of collagen type I (Col1A1)
in rodent cardiac fibroblasts. We found that ISO significantly attenuated AgII-induced expression of Tgfβ1, Tgfβ2, and Col1a1 (Figure 4).

Furthermore, pretreatment with ISO significantly decreased AgII-induced overexpression of Nppb. It encodes the brain natriuretic peptide (BNP) hormone, which is an important biomarker in clinical cardiology. In response to increased cardiac stress, fibrosis, and hypertrophy, BNP is strongly upregulated in the ventricular cardiac muscle.

**DISCUSSION**

In this study, we showed that ISO regulated cardiac fibrosis-related GO and KEGG pathways in hAESCs. We then successfully translated the *in vitro* findings in the *in vivo* model. ISO suppressed myocardial hypertrophy and fibrosis induced by AgII in mice ventricles. In short, the present study demonstrates that ISO could be a valuable pharmaceutical or dietary supplement.

Both pathological fibrosis and hypertrophy of the heart can induce heart failure and other serious cardiac diseases. These are also independent risk factors for cardiac morbidity and mortality. Conventional drugs, including angiotensin-converting enzyme inhibitors, β-blockers, statins, and aldosterone antagonists, are used for the inhibition of cardiac fibrosis and associated complications, however, their effects are secondary to the alleviation of cardiac dysfunction rather than directly targeting cardiac hypertrophy or fibrosis (Zannad et al., 2000; Bauersachs et al., 2001; Klapholz, 2009). Therefore, the discovery of novel compounds with profibrotic potential is urgently needed. Considering the inefficient translation of CVD drugs from hundreds of chemical libraries, a stemcell-based drug screening approach would be most appropriate. In this context, hAESC, a perinatal stem cell that possesses both ESC-like pluripotent...
potential and adult stem cell-like immunomodulatory properties, has drawn great attention from researchers worldwide because of their considerable advantages over other stem cells. hAESCs are readily available, have minimum ethical concerns, and are cost-effective. A number of studies have demonstrated the multilineage differentiation potential of hAESCs (Miki et al., 2005, 2010; Toda et al., 2007; Parolini et al., 2008; Murphy et al., 2010; Zhou et al., 2013). Notably, hAESCs have also been reported to differentiate into cardiomyocytes (Miki et al., 2005; Fang et al., 2012) and endothelial cells (Wu et al., 2017; Serra et al., 2018). Therefore, hAESC is a good alternative tool for screening potential drugs for CVD.

One of the major obstacles of translating hAESCs into the clinic is the heterogeneity in primary amnion epithelial cell population and discrepancies in their cell surface profiling (Centurione et al., 2018) that can be primarily attributed to isolation protocols, gestational age, passage number, and epithelial to mesenchymal transition (Ghamari et al., 2020). However, hAESCs isolated from the adherent subpopulations of passaged primary cells, and cultured in 3D environment may successfully overcome these limitations and may express a higher level of stemness properties (Ferdousi et al., 2019; Furuya et al., 2019). Additionally, protocol for immortalized human amniotic epithelial cells with high expressions of stem cell markers has been reported (Zhou et al., 2013).

In the present study, we have evaluated the cardioprotective potential of ISO in hAESCs. Previously, we have reported that ISO, a flavonol, alleviates hepatic fibrosis in NASH model mice (Ganbold et al., 2019). Although several flavonols have been reported to improve cardiac dysfunction and fibrosis (Suzuki et al., 2007; Li et al., 2013; Geetha et al., 2014; Guo et al., 2015; Zhang et al., 2018), very little is known about the effect of ISO on cardiac hypertrophy and fibrosis. Microarray analysis of ISO-treated hAESCs revealed that ISO has strong antifibrotic effects as well as anti-inflammatory and antioxidative functions. Additionally, ISO showed myogenic and angiogenic differentiation potential in hAESCs. Interestingly, GO analysis showed that ISO targeted similar biological functions in hAESCs that were reported to be regulated in the early stage of AgII-induced cardiac remodeling in a mouse model (Dang et al., 2015).

We hypothesized that ISO could reverse the expression levels of Col1a1 enhanced by AgII. TGFβ1 overexpression is a common pathway for various pathological factors that cause myocardial fibrosis. TGFβ1 has also been shown to prevent or reverse organ fibrosis via the TGFβ/Smad signaling system. Myocardial collagen consists mainly of type I and type III collagen. Type I collagen (Lu et al., 2018) attenuates the network for cardiac muscle cells and strengthens myocardial tissue. Although collagen initially has a structural role in preventing ventricular rupture, an increase in the ratio of type I to type III collagen has been reported in hearts with chronic congestive heart failure, which ultimately leads to myocardial death. The present study showed that the expression of Col1a1 enhanced by AgII was significantly reduced by ISO treatment. We hypothesized that ISO could reverse the expression levels of collagen by attenuating TGFβ1 pathways, thereby suppressing the development of fibrosis.

Furthermore, this study shows that ISO significantly suppressed Nppb gene expression. Nppb encodes BNP hormone, which is an important biomarker in clinical cardiology (Diamandis et al., 2014). In response to increased cardiac stress, fibrosis, and hypertrophy, BNP is strongly upregulated in the ventricular cardiac muscle (Kerkelä et al., 2015). BNP inhibits renin secretion, thereby inhibiting the renin-angiotensin-aldosterone system. Therefore, our findings indicate that ISO has the effects on cardiac hypertrophy and fibrosis.

It has been reported that ISO ameliorates cardiac hypertrophy and fibrosis induced by aortic banding (Gao et al., 2017), however, there has been no report on the effect of ISO on...
AgII loading. Although the mechanism of angiotensin-induced cardiac disease has largely been clarified, researchers are still searching for effective drugs. A commonly used animal model is the subcutaneous infusion of AgII into mice. Osmotic pumps are designed to continuously deliver compounds to small animals at a constant rate. This technique is commonly used to induce AF, aortic aneurysm, and hypertension, leading to serious heart disease or sudden death (Wu et al., 2019). AgII 1,000 ng/kg/min is commonly used. Based on this background, we conducted this experiment with reference to this dose. AgII, a vasoactive peptide, is a key regulator of hypertension, inflammatory response, hypertrophy, and fibrosis through the regulation of multiple signaling pathways, such as NF-κB and TGFβ1/Smad (Shang et al., 2008). Our results indicated that chronic AgII infusion remarkably induced left ventricular wall extension, dilation, pathological hypertrophy, fibrosis, and macrophage infiltration, and that ISO completely eliminated these abnormalities induced by AgII. ISO significantly suppressed fibrosis in the interstitial myocardium and around blood vessels showed in MT staining. Furthermore, ISO prevented the living cells surrounded by dead cells that eventually became oxygen-deficient, leading to heart failure and sudden death.

CONCLUSION

Our evidence suggests that hAESC has important implications as an alternative tool for the screening and development of drugs and dietary supplements in future. Our results also demonstrate that ISO could effectively suppress hypertrophy and fibrosis induced by AgII in cardiac tissue by regulating TGFβ pathways. ISO could have beneficial effects on potential clinical consequences of CVDs by regulating the activity of the renin-angiotensin system.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this article and its Supplementary Information. Microarray data are deposited in the Gene Expression Omnibus (GEO) under accession number: GSE153149 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153149).

REFERENCES

Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A., et al. (2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44, W147–W153.
Bang, C. N., Soliman, E. Z., Simpson, L. M., Davis, B. R., Devereux, R. B., and Okin, P. M. (2017). Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT Study. Am. J. Hypertens. 30, 914–922. doi: 10.1093/ajh/hpx067
Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., and Erlt, G. (2001). Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104, 982–985.

ETHICS STATEMENT

The protocol for the hAESC study was reviewed and approved by the Ethical Review Committee of the University of Tsukuba. Informed written consent was obtained from the mothers who donated the placenta after delivery. After receiving approval from the Institutional Animal Experiment Committee of the University of Tsukuba, animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, the Regulation for Animal Experiments in the University of Tsukuba, and the Fundamental Guideline for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology of Japan.

AUTHOR CONTRIBUTIONS

KA: investigation. KA and FF: formal analysis, data curation, software, visualization, and writing-original draft. DX: methodology, validation, supervision, and resources. KT: methodology, resources, supervision, project administration, funding acquisition, and writing-review and editing. All authors made substantial contributions to this article and approved the final version of the article.

FUNDING

This research was partially supported by the Japan Science and Technology Agency (JST), Science and Technology Research Partnership for Sustainable Development (SATREPS, Grant No. JPMISA1506).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.578197/full#supplementary-material

Centurione, L., Passaretta, F., Centurione, M. A., De Munari, S., Vertua, E., Silini, A., et al. (2018). Mapping of the human placenta: experimental evidence of amniotic epithelial cell heterogeneity. Cell Transpl. 27, 12–22.
Chen, K. G., Mallon, B. S., McKay, R. D. G., and Robey, P. G. (2014). Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutic use. Cell Stem Cell 14, 13–26. doi: 10.1016/j.stem.2013.12.005
Dang, M.-Q., Zhao, X.-C., Lai, S., Wang, X., Wang, L., Zhang, Y.-L., et al. (2015). Gene expression profile in the early stage of angiotensin II-induced cardiac remodeling: a time series microarray study in a mouse model. Cell. Physiol. Biochem. 35, 467–476.
De Coppi, P., and Atala, A. (2019). "Stem cells from the amnion," in Principles of Regenerative Medicine, 3rd Edn, eds A. Atala, R. Lanza, A. G. Mikos, and R. Nerem (Boston: Academic Press), 133–148.
Kerkela, R., Ulvila, J., and Magga, J. (2015). Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J. Am. Heart Assoc. 4, 1–13. doi: 10.1161/JAHA.115.002243

Klapolz, M. (2009). β-Blocker Use for. (the)Stages of Heart Failure. Amsterdam: Elsevier; 718–729. doi: 10.4065/s4.8.718

Li, M., Jiang, Y., Jeng, W., Sun, B., Miao, C., and Ren, L. (2013). Quercetin provides greater cardioprotective effect than its glycoside derivative rutin on isoproterenol-induced cardiac fibrosis in the rat. Can. J. Physiol. Pharmacol. 91, 951–959. doi: 10.1139/cjpp-2012-0432

Li, Y., and Kilian, K. A. (2015). Bridging the gap: from 2D cell culture to 3D microengineered extracellular matrices. Adv. Healthc. Mater. 4, 2780–2796. doi: 10.1002/adhm.201500427

Lijnen, P. J., Petrov, V. V., and Fagard, R. H. (2000). Induction of cardiac fibrosis by transforming growth factor-β. Mol. Genet. Metab. 71, 418–435. doi: 10.1006/mgen.2000.3032

Lu, Y., Kamel-EI Sayed, S. A., Wang, K., Tieide-Lewis, A. L., Grillo, M. A., Veno, P. A., et al. (2018). Live imaging of type I collagen assembly dynamics in osteoblasts stably expressing GFP and mCherry-tagged collagen constructs. J. Bone Miner. Res. 33, 1116–1182. doi: 10.1002/jbmr.3409

Marwick, T. H., Gillette, T. C., Aurigemma, G., Chirinos, J., Derrameaux, G., Galderisi, M., et al. (2015). Recommendations on the use of echocardiography in adult hypertension: a report from the european association of cardiovascular imaging (EACVI) and the american society of echocardiography (ASE). J. Am. Soc. Echocardiogr. 28, 727–754. doi: 10.1016/j.echo.2015.05.002

Miki, T. (2018). Stem cell characteristics and the therapeutic potential of amniotic epithelial cells. Am. J. Reprod. Immunol. 80:e13093. doi: 10.1111/aji.13003

Miki, T., Lehmann, T., Cai, H., Stolz, D. B., and Strom, S. C. (2005). Stem cell characteristics of amniotic epithelial cells. Stem Cells 23, 1549–1559. doi: 10.1634/stemcells.2004-0357

Miki, T., Marongiu, F., Dorko, K., Ellis, E. C., and Strom, S. C. (2010). Isolation of amniotic epithelial stem cells. Curr. Protoc. Stem Cell Biol. 12, 1–31. 3.10. doi: 10.1002/9780470151808.sde103412

Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sahag, S., Lehar, J., et al. (2003). PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–272. doi: 10.1038/ng1180

Murphy, S., Rosli, S., Acharya, R., Mathias, L., Lim, R., Wallace, E., et al. (2010). Amnion epithelial cell isolation and characterization for clinical use. Curr. Protoc. Stem Cell Biol. 13, 6.1–6.25. doi: 10.1002/9780470151808.sde106613

Parolini, O., Alviano, F., Bagnara, G. P., Bilic, G., Bühring, H. J., Evangelista, M., et al. (2018). Exploring the potential role of rosmarinic acid in neuronal differentiation of human amniotic stem cells reveals therapeutic potential for Alzheimer’s disease. Front. Bioeng. Biotechnol. 6:44. doi: 10.3389/fnins.2008.211

Shang, L. L., Sanyal, S., Pfahnl, A. E., Jiao, Z., Allen, J., Liu, H., et al. (2008). NF-κB phosphorylation are coordinately downregulated in human diabetes. Proc. Natl. Acad. Sci. U.S.A. 105, 16772–16777. doi: 10.1073/pnas.0807312105

Suzuki, J. I., Ogawa, M., Futamatsu, H., Kosuge, H., Sagesaka, Y. M., and Isobe, M. (2003). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived biospecimen resources for drug discovery: approach of tsukuba human tissue. Regul. Sci. Med. Prod. 6, 57–63. doi: 10.14982/rsmp.6.57

Aronuma et al. hAESCs for Screening of Cardioprotective Effects of Isorhamnetin
Aonuma et al. hAESCs for Screening of Cardioprotective Effects of Isorhamnetin

Toda, A., Okabe, M., Yoshida, T., and Nikaido, T. (2007). The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J. Pharmacol. Sci. 105, 215–228.

Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., and Blaxall, B. C. (2016). Cardiac fibrosis: the fibroblast awakens. Circ. Res. 118, 1021–1040. doi: 10.1161/CIRCRESAHA.115.306565

Weber, K. T., Sun, Y., and Diez, J. (2008). Fibrosis: a living tissue and the infarcted heart. J. Am. Coll. Cardiol. 52, 2029–2031. doi: 10.1016/j.jacc.2008.09.012

Wu, Q., Fang, T., Lang, H., Chen, M., Shi, P., Pang, X., et al. (2017). Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells. Int. J. Mol. Med. 39, 918–926. doi: 10.3892/ijmm.2017.2897

Yang, J. H., Kim, S. C., Kim, K. M., Jang, C. H., Cho, S. S., Kim, S. J., et al. (2016). Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. Eur. J. Pharmacol. 783, 92–102. doi: 10.1016/j.ejphar.2016.04.042

Yang, P.-J., Yuan, W.-X., Liu, J., Li, J.-Y., Tan, B., Qiu, C., et al. (2018). Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol. Sin. 39, 1305–1316. doi: 10.1038/aps.2018.22

Yue, L., Xie, J., and Nattel, S. (2011). Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 89, 744–753. doi: 10.1093/cvr/cvq329

Zannad, F., Alla, F., Dousset, B., Perez, A., and Pitt, B. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102, 2700–2706. doi: 10.1161/01.CIR.102.22.2700

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.